Meh..<p>You can resell a test so long as you follow the rules of the contract of the manufacturer and applicable CLIA and other FDA regulations.  These are subject to audit etc... You should not report clinical results from tests not run in a CLIA or FDA approved way.  So if a test is run on Siemens for reporting clinical results then the audit goes on that pathway.   Diluting the pinprick blood to run on a test that requires larger volumes probably won&#x27;t work either unless they&#x27;ve shown it does and that of course depends on the CLIA and&#x2F;or FDA regulations around the test to prove equivalence.  It seems like it won&#x27;t work since the tests have specific input requirements (e.g. 100mL plasma vs 1mL).  You might be able to go the other way.. but you miss the cellular and interstitial components that may add noise (e.g. potassium which cells bioaccumulate etc)..<p>Which other rules apply probably depends on interpretation of whether these are lab developed tests or FDA regulated and this area may require clarification etc... which will depend test to test etc...<p>Otherwise it sounds like they may have calibration issues which are normal. Outliers happen all the time. If the technology doesn&#x27;t have some fundamental limit of detection based on the sample volume then they just need to keep iterating.  Or the components of blood from the pin prick differ significantly from blood taken from the vein.  The data may just be noisy.  What that noise level is matters in terms of the detection limits.  It is probably too early to tell.  Internally they will be tracking this and trying to figure it out.<p>So this article seems like click bait, but what do I know.